21^st Annual European Pharma Congress May 20-22, 2019 Mövenpick Hotel Zürich Regensdorf, Switzerland

Dr. Bimal Roy Krishna is currently Professor and Director of Pharmacology at the College of Osteopathic Medicine, Touro University in Nevada. He obtained a Bachelor of Science (First Class Honors) in Pharmacology and Physiology and a Doctor of Philosophy, Medicine (OB/GYN/Pharmacology) from Monash University in Australia. Dr. Krishna also teaches for the Step 1 USMLE and COMLEX reviews for Kaplan Medical throughout the United States and in UAE, Europe, Saudi Arabia, India, Mexico and the Caribbean. He has been teaching online for Kaplan University for over 7 years. He has contributed to numerous publications and is a member of a number of organizations including Fellow-American College of Clinical Pharmacology.

His research background is in maternal and neonatal pharmacology specifically looking at materno-fetal transfer utilizing the perfused human placental and cultured syncytiotrophoblast model. Complementary and Alternative medicine is another area of interest.

The author received an honorable PhD in mathematics and majored in engineering at MIT. He attended different universities over 17 years and studied seven academic disciplines. He has spent 20,000 hours in T2D research. First, he studied six metabolic diseases and food nutrition during 2010-2013, then conducted research during 2014-2018. His approach is “math-physics and quantitative medicine” based on mathematics, physics, engineering modeling, signal processing, computer science, big data analytics, statistics, machine learning, and AI. His main focus is on preventive medicine using prediction tools. He believes that the better the prediction, the more control you have.

The author spent seven years and 18,000 hours to study, analyze and research his chronic disease conditions. Here is the comparison between 2010 and 2017: Weight: 205 / 172 lbs. Waistline: 44 / 34 inches PPG: 350 / 116 mg/dL FPG: 185 / 119 mg/dL Daily glucose: 280 / 117 mg/dL A1C: 10.0 / 6.1 % ACR: 116 / 12 mg/mmol Triglycerides: 1161 / 69 mg/dL He used mathematics, physics, engineering modeling, and computer science (big data analytics and AI) to derive the mathematical metabolism model and three prediction tools for weight, FPG, and PPG with >30 input elements. This study includes 11 categories: weight, glucose, blood pressure, lipids, food, water, exercise, sleep, stress, life pattern regularity, time, with ~500 input and output elements. He collected more than 1 million “clean” data over 7 years. He defined two new terms known as the Metabolism Index (MI) and General Health Status Unit (GHSU). The “health state” is expressed as the “break-even” line which is 73.5%; above this percentage is regarded “unhealthy” and below the break-even line is “healthy”. The results showed that he was very unhealthy (80%-110%) before 2013. The curve went through a sharp decline in 2014 due to his research. After 2015, he was “healthy” (60%-70%). As of 12/21/2017, his MI is 55.3% and GHSU is 56.1%. All of his previous lab test results confirmed with the diagram showing his chronic disease conditions are well under control.

Professor Jun O. Liu received his B.S. degree in Chemistry from Nanjing University. He went to the US through the Chemistry Graduate Program, obtaining his MS in organic chemistry from the Ohio State University and his PhD in biochemistry from MIT. He did his postdoc at Harvard University and served as a research associate at the NIH. He served as an assistant and associate professor of chemistry and biology at MIT Center for Cancer Research before moving to his current position as a professor of pharmacology and oncology at Johns Hopkins School of Medicine. His main research interest lies in the interface between chemistry, biology and medicine. In particular, his group has been focusing on the use of natural products and existing drugs as molecular probes of various cellular processes and as novel drug leads.

Our primary research interest lies at the interface between chemistry, biology and medicine. We employ high-throughput screening to identify modulators of various cellular processes and pathways that have been implicated in human diseases from cancer to autoimmune diseases. Once biologically active compounds are identified, they will serve as both probes of the biological processes of interest and leads for the development of new drugs for treating human diseases. Among the biological processes of interest are cancer cell growth and mestastasis, apoptosis, angiogenesis, calcium-dependent signaling pathways, eukaryotic transcription and translation. Some of the ongoing projects are highlighted herein.

Dr. Akala is Professor of Pharmaceutics, Chair, Howard University Institutional Animal Care and Use Committee d Development (IACUC) and Director, Laboratory for Nanomedicine, Drug Delivery, and Pharmaceutical & Biopharmaceutical Drug Products Design and Development. Dr. Emmanuel O. Akala received his B. Pharm. and M.Sc.(Pharmaceutics) from The University of Ife (now OAU) Nigeria and Ph.D. (Pharmaceutics) from The University of Manchester, England. He was a DAAD Research Scientist in Biopharmaceutics and Pharmaceutical Technology at The University of Munster, Germany, NIH-Fogarty International Fellow in Pharmaceutics and Bioengineering at The University of Utah (USA). He is a registered and immunization Pharmacist in Utah, Maryland and Washington DC.

Dr. Akala’s research interest is in novel and conventional drug products’ design and development. Current research efforts focus on Nanotechnological Platforms for the Delivery of Bioactive (Drugs) and Diagnostic Agents.

Dr Irina Ermolina is a senior lecturer in Pharmaceuticals in the School of Pharmacy, De Montfort University. She gained her PhD degree in Molecular Physics in Institute of Biochemistry and Biophysics, Russian Academy of Sciences, Kazan, Russia. Prior to joining the DMU as an academic staff, Dr Ermolina was employed as Postdoctoral Research Fellow at Glasgow University and Southampton University. Previously she worked as a senior researcher in Institute of Biochemistry and Biophysics, Kazan, Russian Academy of Sciences. Dr Ermolina now specializes in characterization of physical properties of pharmaceutical solids and powders studied by different analytical techniques; development and characterization of hydrogels as drug delivery systems; dielectric properties biological systems (proteins, DNA, cells, disaccharides); stability characterization of freeze-dried pharmaceuticals; the dynamic structure of proteins in solutions and membrane films.

Freeze-drying Pharmaceuticals Dielectric spectroscopy Thermoanalytical methods Terahertz spectroscopy Characterization of hydrogels.

Yavuz is the CEO of MAIN , one of the fastest growing angel investors network in MENA & chairman of Istanbul Consulting Group. ICG(Istanbul Consulting Group) was founded in 2013 and provided guidance to the Turkish ministry of health as part of a World Bank project.Yavuz is currently the Co-Founder of BioCube İstanbul Bioentrepreneurship & Innovation Center and Corporate Communication Director of Sumitomo Group/ Expel İlaç Archem Diagnostics Endmed and Diagen. He previously managed the largest distributor of Siemens Healthcare in Turkey managing 250 employees and director of Avcılar Hospital R&D Center, Chief Medical Officer of Lifematrix GmbH. Previously he worked as the Market Access & Health Policy Director for AIFD in Turkey. Yavuz previously worked as the Vice President of Ipsen pharmaceutical and Director of Teva pharmaceutical in USA managing large clinical trials as well as Investigator Initiated Trials and developing relationships with Key Opinion Leaders. Previously, Yavuz was the Associate Director at KV Pharmaceuticals and Director in Clinical Development department at Forest Laboratories. Yavuz earned his MD from the Faculty of Medicine, University of Ankara in Ankara, Turkey. He completed a clinical internship at Baylor College of Medicine in Houston, followed by continued research training at The University of Texas MD Anderson Cancer Center in Houston. He recently completed his Executive MBA at the Olin Business School at Washington University in St. Louis. Yavuz currently resides with his wife Dr. Kamile Sılay and their two daughters and one son in Ankara,Turkey. Dr. Silay is serving as the CEO of MAIN, one of the fastest growing angel investors network in MENA region & Chairman of İstanbul Consulting Group in Europe, providing clinical trial administration, market access, medical writing, patient recruitment, retention, regulatory and medical affairs support, drug repositioning for hospitals, academic institutions and pharmaceutical companies from preclinical to post marketing stages for several years. Dr. Silay is also providing comprehensive and strategic consulting services for the approval of Drugs and Medical Devices and attended several meetings with FDA, EMA, Health Canada and Turkish Health authorities and social security institute.Dr. Silay in USA, most recently worked as the Vice President, Medical Affairs, and head of Medical Affairs Neurology in the US headquarters Basking Ridge, New Jersey reporting to the President and CEO of Ipsen North America where he was key in building a Neurology Franchise by hiring many employees. Dr. Silay is a senior consultant, project manager, executive physician scientist, certified clinical research professional in the healthcare ( pharmaceutical, medical device, hospital chains) industry with an Executive MBA degree from the Olin Business School at Washington University in St. Louis which is ranked #2 in United States of America by Wall Street Journal in 2010. Dr. Silay is a member of American Academy of Neurology, chief editor of Journal of Developing Drugs, an editorial board member of Expert opinion on Emerging Drugs, a current ad-hoc reviewer at the NIH ( National Institute of Health) and NINDS, past speaker at DIA ( Drug Information Association) and member of DIA SIAC’s for Good Clinical Practice/Quality Assurance Special Interest Activity Community (GCP/QA SIAC), Clinical Trial Registry/Results Disclosure Working Group (CTR/RD Working Group), Natural Health Products. , MDS (Movement Disorder Society) , current secretary general of HEPA (Health Economics& Policy Association), charter and previous president of AMSA (American Medical Student Association) Turkey, previous president of SOCRA (Society of Clinical Research Associates) in New Jersey, board of directors member at the SoPE and founder of SoPE(Society of Physician Entrepreneurs) Turkey chapter. Dr. Silay is a recognized senior consultant executive in the public health, PPP, health economics and pharmaceutical industry with a track record of conducting successful, carefully designed outcomes trials as well as randomized double blind placebo controlled clinical trials in CNS (Central Nervous System) therapeutic area such as Parkinson’s, MS (Multiple Sclerosis), Stroke, head trauma, Fibromyalgia, Tourette syndrome, Alzheimer’s disease as well as Pulmonary Critical Care/ Lung transplant, Cardivascular (Cardiac stent, MI, Ambulatory Blood pressure monitoring trials) and Oncology therapeutic areas. Dr. Silay, a dual citizen of U.S.A. and Turkey was born in Turkey and educated in Turkey, Germany and U.S.A. He completed his medical School at The University of Ankara in Turkey and his internship at Baylor College of Medicine and University of Texas in Houston, Texas. He attended a Physician Scientist Training Program at The MD Anderson Cancer Center of University of Texas. Dr. Silay worked on projects with several Pharmaceutical companies such as Astellas, Chiron, Fugisawa, Nabi Biopharmaceutical, Forest Pharmaceuticals, KV Pharmaceuticals, Medtronics, Deep Breeze, Teva, Ipsen as well as governmental organizations such as NIH, Chest foundation, American heart association grants, FDA, Turkish minister of Health and the World Bank As a prolific scientific writer he published extensively with more than 15 peer reviewed article and more than 100 platform and abstract presentation at the academic and industry level in national and international meetings. Dr. Silay is currently serving as the Chairman of the Istanbul Consulting Group (ICG) . He provides guidance and support to Turkish Ministry of health through World bank project. As the former General Manager of the largest distributor of Siemens healthcare company with ~220 employees, he played key role in developing mobile Breast cancer screening program for Turkish and Syrian refugees in Turkey. As a BioPharma CEO, Carveout, Turnaround Specialist he is known as, Entrepreneur Doctor & "International Healthcare Executive (Pharmaceutical, Hospital Chain, Diagnostic & Medical Device)", Management Consultant, "Business, Strategy, Marketing Savvy Physician. He has Proven ability to build high performing teams and productive organizations, turn around brands, and build revenue in diverse markets. As the former director, Market Access & Health Policy for AIFD( Research Based Pharmaceutical Companies) which the 40 members represent all major global pharmaceutical companies, 650 billion dollars of 1 billion dollar Global Pharmaceutical market. He represented pharmaceutical companies and was in discussion with all ministerial levels, including ministry of health, finance, labor, development and science& technology in Turkey.

Neurology, Pulmonary Critical Care, Rheumatology, Oncology and related therapeutic areas within academics and industry. regulatory processes, identifying and addressing risk management issues throughout lifecycle, presentation development to large payers, safety monitoring, designing and conducting clinical trials.

Will be updated soon

Will be updated soon

Masahiro Onuma is a President of Trisguide Ltd in Tokyo,Japan. He has expertise in oxidative disease prevention to use non-medical product based on GSK’s experience of Allopurinol which is the strongest anti-oxidant efficacy in this world. He creates new indication of Allopurinol for stomatitis induced by cancer treatment which was approved by the Japanese Cancer treatment committee to propose new mechanism of Allopurinol for anti-oxidant. And now, there are so many new research papers of Allopurinol in the world.

Oxidative disease prevention to use non-medical product based on GSK’s experience of Allopurinol which is the strongest anti-oxidant efficacy in this world. He creates new indication of Allopurinol for stomatitis induced by cancer treatment which was approved by the Japanese Cancer treatment committee to propose new mechanism of Allopurinol for anti-oxidant. And now, there are so many new research papers of Allopurinol in the world.

Dr Sergey Suchkov, MD, PhD was born in 11.01.1957, a researcher-immunologist, a clinician, graduated from Astrakhan State Medical University, Russia, in 1980. Suchkov has been trained at the Institute for Medical Enzymology, The USSR Academy of Medical Sciences, National Center for Immunology (Russia), NIH, Bethesda, USA, and British Society forImmunology to cover 4 British university facilities. Since 2005, Dr Suchkov has been working as Professor of I.M. Sechenov First Moscow State Medical University and of A.I.Evdokimov Moscow State Medical and Dental University. From 2007, Suchkov is the First Vice-President and Dean of School of PPPM Politics and Management of the University of World Politics and Law. In 1991-1995, Dr Suchkov was a Scientific Secretary-in-Chief of the Editorial Board of the International Journal Biomedical Science (Russian Academy of Sciences and Royal Society of Chemistry, UK) and The International Publishing Bureau at the Presidium of the Russian Academy of Sciences. In 1995-2005, Suchkov was a Director of the Russian-American Program in Immunology of the Eye Dis-eases.Dr Suchkov is a member of EPMA (European Association of Predictive, Preventive and Person-alized Medicine,Brussels-Bonn), a member of the NY Academy of Sciences, a member of the Editorial Boards for Open Journal of Immunology, EPMA J., and Personalized Medicine Universe, and others. Dr Suchkov is known as a co-author of the Concept of post-infectious clinical and immunological syn-drome, co-author of a concept of abzymes and their impact into the pathogenesis ofautuimmunity conditions, and as one of the pioneers in promoting the Concept of PPPM into a practical branchof health services. Now r Suchkov is a Chair of Dept for Personalized and Translational Medicine, and Director, Center for Personalized and Translational Reproductology, I.M.Sechenov First Moscow State Medical University. Prof Sergey Suchkov, MD, PhD Chair, Dept for Personalized and Translational Medicine, Director, Center for Personalized Reproductology and Pediatrics, I.M.Sechenov First Moscow State Medical University, Moscow, Russia Member, EPMA, Brussels, EU Member, PMC, Washington, DC, USA Member, ISPM, Tokyo, Japan Member, New York Academy of Sciences Member, ACS, USA Member, AHA, USA Member, AMEE, Dundee, UK Secretary General, UCC, Cambridge, UK

A Researcher-immunologist.

Arik Dahan is a professor of Clinical Pharmacology at Ben-Gurion University of the Negev, He holds Ph. D. degree in Pharmacy and published more than 20 Research articles in reputed national and international journals. He is also an Adjunct Professor of Pharmaceutical Sciences at the College of Pharmacy, University of Michigan. Dr. Dahan received his Ph.D. (2007) from the Hebrew University of Jerusalem. He was a Post-Doctoral Research Fellow at the University of Michigan (2007-2010) with Professor Gordon L. Amidon. Dr. Dahans research interest is the integration of up-to-date molecular/cellular mechanistic investigations of drug disposition in the context of the human body. In implementing this molecular biopharmaceutical approach to ADME research, Dr. Dahan is seeking to enable mechanistic-based successful solutions to drug delivery/therapy, in challenging scenarios e.g. low-solubility, low-permeability, extensive metabolism, poor site targeting, various pathophysiological conditions, and pediatrics. He has published over 50 top-notch Journal papers, and contributed chapters to 6 books.

BCS (Biopharmaceutics Classification System); Biopharmaceutics; Bioequivalence; Drug Solubility; Drug Targeting; Intestinal Permeability; Oral Drug Absorption; Pharmaceutical Sciences

Prof. Mire Zloh graduated in Physical Chemistry from the University of Belgrade (Yugoslavia) in 1987. He was then awarded an MSc in Physical Chemistry from the same university in 1992. His research in structural biology resulted in a PhD in Chemistry from the University of London in 1998 with a thesis entitled "Conformational Studies of the High Affinity IgE Receptor Peptides and Domains by NMR and Molecular Modelling". He was elected as a Fellow of the Royal Society of Chemistryand he is a member of Academy of Pharmaceutical Sciences, Molecular Graphics and Modelling Society, Serbian Chemical Society and Society of Physical Chemists of Serbia. Prof. Zloh was serving as a membership secretary for the now defunct RSC Molecular Modelling interest group.Mire Zloh is Emeritus Professor of Medicinal Chemistry at the University of Hertfordshire. He was the Head of Pharmaceutical Chemistry in the Department of Pharmacy from January 2013 and Research Professor within the Centre for Health Services and Clinical Research from September 2015 until September 2017. Prior to his present position was Senior Lecturer at the UCL School of Pharmacy and was responsible for the integrated structural chemistry service that provides NMR, MS and CHN analysis to internal and external users. He was an Assistant Professor at the Faculty of Pharmacy in Belgrade for the Clinical Chemistry Instrumentation course before moving to London. From 2002 to 2003, he was a tutor counsellor for the Open University. Prof. Zloh was Deputy Director on the MSc Course in Drug Discovery at UCL School of Pharmacy.

Basic Life Sciences

Saturnino is Professor of Medicinal Chemistry in University of Basilicata, Italy and associated with Chemical Biology Letters ( http://pubs.iscience.in/journal/index.php/cbl/pages/view/editorialboard ) as Editorial Advisory Board Member.

Medicinal Chemistry

B.Sc. (University of Calgary) Ph.D. (University of Alberta) Assoc. Prof. and Director, Metabolic Res. Lab., Dept. Biomedical Physiology, BPK-9625

updated soon...

Recently He is a Professor and Researcher.

Biomedical Engineering and

Prof. Nahla El-Sayed El-Ashmawy is Professor of Biochemistry and Molecular Biology. Currently, she is the Head of Biochemistry Department and Dean, Faculty of Pharmacy, Tanta University, Egypt. She has 64 publications in the field of study of biochemical mechanisms of action of drugs and natural products and evaluation of their biological activity. The scope of the research also involves the search for new noninvasive biomarkers for early detection and diagnosis of diseases. Stem cell research is conducted in her lab and is directed towards modulation of immune system and the use of adoptive cellular immunotherapy as a strategy for treatment.

Biochemistry and Molecular Biology

PhD, Utkal University, Bhubaneswar, Orissa, India

Pharmaceutics

Akmal Sakr, is Ph D holder, manager of Conservation center, National Museum of Egyptian Civilization (NMEC), Cairo, Egypt.

His intensive expertise in applying biotechnology in conservation of antiquities, in particular production and application of enzymes and antibiotics as eco-friendly methods in conservation of deteriorated cultural heritage objects.